Valion Bio, Inc. (VBIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseVBIO / S&P -41.31% / 15.20% |
LoseVBIO / S&P VBIO unavailable / 15.00% |
LoseVBIO / S&P VBIO unavailable / 50.40% |
| 2026-Q10/3 |
LoseVBIO / S&P -38.90% / -4.33% |
LoseVBIO / S&P VBIO unavailable / 11.30% |
LoseVBIO / S&P VBIO unavailable / 27.70% |
| 2025-Q40/3 |
LoseVBIO / S&P -49.83% / 2.65% |
LoseVBIO / S&P VBIO unavailable / 9.00% |
LoseVBIO / S&P VBIO unavailable / 13.40% |
| 2025-Q30/3 |
LoseVBIO / S&P -30.36% / 8.12% |
LoseVBIO / S&P -49.63% / 4.61% |
LoseVBIO / S&P VBIO unavailable / 13.45% |
| 2025-Q21/3 |
WinVBIO / S&P 62.11% / 10.94% |
LoseVBIO / S&P -58.49% / 4.83% |
LoseVBIO / S&P -87.62% / 10.63% |
| 2025-Q10/3 |
LoseVBIO / S&P -56.48% / -4.27% |
LoseVBIO / S&P -54.50% / 4.98% |
LoseVBIO / S&P -86.08% / 10.57% |
| 2024-Q41/3 |
WinVBIO / S&P 38.40% / 2.41% |
LoseVBIO / S&P -33.67% / 5.25% |
LoseVBIO / S&P -77.69% / 6.15% |
| 2024-Q31/3 |
LoseVBIO / S&P -35.90% / 5.89% |
LoseVBIO / S&P -22.00% / 5.89% |
WinVBIO / S&P 344.80% / 6.11% |
| 2024-Q21/3 |
LoseVBIO / S&P -68.80% / 4.28% |
LoseVBIO / S&P -21.73% / 5.38% |
WinVBIO / S&P 179.71% / 5.12% |
| 2024-Q11/3 |
LoseVBIO / S&P -30.56% / 10.56% |
LoseVBIO / S&P -36.61% / 5.71% |
WinVBIO / S&P 213.91% / 5.59% |
| 2023-Q41/3 |
LoseVBIO / S&P 4.05% / 11.69% |
LoseVBIO / S&P -36.12% / 6.81% |
WinVBIO / S&P 264.38% / 7.78% |
| 2023-Q31/3 |
LoseVBIO / S&P -83.68% / -3.27% |
LoseVBIO / S&P -32.66% / 7.52% |
WinVBIO / S&P 51.61% / -5.03% |
| 2023-Q21/3 |
LoseVBIO / S&P -29.80% / 8.74% |
LoseVBIO / S&P -12.33% / 9.50% |
WinVBIO / S&P 3441.67% / -8.57% |
| 2023-Q12/3 |
LoseVBIO / S&P -76.41% / 7.50% |
WinVBIO / S&P 31.35% / 10.77% |
WinVBIO / S&P 2868.93% / -15.69% |
| 2022-Q42/3 |
LoseVBIO / S&P -55.86% / 7.56% |
WinVBIO / S&P 46.46% / 11.88% |
WinVBIO / S&P 2010.79% / -17.99% |
| 2022-Q30/3 |
LoseVBIO / S&P -25.64% / -4.88% |
LoseVBIO / S&P VBIO unavailable / 13.47% |
LoseVBIO / S&P VBIO unavailable / -1.41% |
| 2022-Q21/3 |
WinVBIO / S&P 21.12% / -16.10% |
LoseVBIO / S&P VBIO unavailable / 13.71% |
LoseVBIO / S&P VBIO unavailable / 11.04% |
| 2022-Q10/3 |
LoseVBIO / S&P -58.51% / -4.60% |
LoseVBIO / S&P VBIO unavailable / 15.97% |
LoseVBIO / S&P VBIO unavailable / 42.23% |
| 2021-Q40/3 |
LoseVBIO / S&P VBIO unavailable / 11.03% |
LoseVBIO / S&P VBIO unavailable / 15.00% |
LoseVBIO / S&P VBIO unavailable / 96.40% |
| 2021-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 0.58% |
LoseVBIO / S&P VBIO unavailable / 10.77% |
LoseVBIO / S&P VBIO unavailable / 69.42% |
| 2021-Q20/3 |
LoseVBIO / S&P VBIO unavailable / 8.55% |
LoseVBIO / S&P VBIO unavailable / 6.58% |
LoseVBIO / S&P VBIO unavailable / 51.81% |
| 2021-Q10/3 |
LoseVBIO / S&P VBIO unavailable / 6.17% |
LoseVBIO / S&P VBIO unavailable / -1.06% |
LoseVBIO / S&P VBIO unavailable / 7.39% |
| 2020-Q40/3 |
LoseVBIO / S&P VBIO unavailable / 12.15% |
LoseVBIO / S&P VBIO unavailable / -3.72% |
LoseVBIO / S&P VBIO unavailable / -33.42% |
| 2020-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 8.93% |
LoseVBIO / S&P VBIO unavailable / -2.04% |
LoseVBIO / S&P VBIO unavailable / -27.10% |
| 2020-Q20/3 |
LoseVBIO / S&P VBIO unavailable / 20.54% |
LoseVBIO / S&P VBIO unavailable / -0.46% |
LoseVBIO / S&P VBIO unavailable / -27.11% |
| 2020-Q10/3 |
LoseVBIO / S&P VBIO unavailable / -19.60% |
LoseVBIO / S&P VBIO unavailable / 3.47% |
LoseVBIO / S&P VBIO unavailable / -14.75% |
| 2019-Q40/3 |
LoseVBIO / S&P VBIO unavailable / 9.07% |
LoseVBIO / S&P VBIO unavailable / 5.36% |
LoseVBIO / S&P VBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 1.70% |
LoseVBIO / S&P VBIO unavailable / 5.02% |
LoseVBIO / S&P VBIO unavailable / 0.21% |
| 2019-Q20/3 |
LoseVBIO / S&P VBIO unavailable / 4.30% |
LoseVBIO / S&P VBIO unavailable / 6.64% |
LoseVBIO / S&P VBIO unavailable / 8.65% |
| 2019-Q10/3 |
LoseVBIO / S&P VBIO unavailable / 13.65% |
LoseVBIO / S&P VBIO unavailable / 8.12% |
LoseVBIO / S&P VBIO unavailable / 14.29% |
| 2018-Q40/3 |
LoseVBIO / S&P VBIO unavailable / -13.52% |
LoseVBIO / S&P VBIO unavailable / 9.05% |
LoseVBIO / S&P VBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 7.71% |
LoseVBIO / S&P VBIO unavailable / 10.21% |
LoseVBIO / S&P VBIO unavailable / 19.06% |
| 2018-Q20/3 |
LoseVBIO / S&P VBIO unavailable / 3.43% |
LoseVBIO / S&P VBIO unavailable / 9.03% |
LoseVBIO / S&P VBIO unavailable / 14.46% |
| 2018-Q10/3 |
LoseVBIO / S&P VBIO unavailable / -0.76% |
LoseVBIO / S&P VBIO unavailable / 7.68% |
LoseVBIO / S&P VBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseVBIO / S&P VBIO unavailable / 6.64% |
LoseVBIO / S&P VBIO unavailable / 7.03% |
LoseVBIO / S&P VBIO unavailable / 13.82% |
| 2017-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 4.48% |
LoseVBIO / S&P VBIO unavailable / 5.68% |
LoseVBIO / S&P VBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseVBIO / S&P VBIO unavailable / 3.09% |
LoseVBIO / S&P VBIO unavailable / 4.83% |
LoseVBIO / S&P VBIO unavailable / 17.74% |
| 2017-Q10/3 |
LoseVBIO / S&P VBIO unavailable / 6.07% |
LoseVBIO / S&P VBIO unavailable / 3.67% |
LoseVBIO / S&P VBIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseVBIO / S&P VBIO unavailable / 3.82% |
LoseVBIO / S&P VBIO unavailable / 2.09% |
LoseVBIO / S&P VBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseVBIO / S&P VBIO unavailable / 3.85% |
LoseVBIO / S&P VBIO unavailable / 0.20% |
LoseVBIO / S&P VBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.02% | 20.78% |
| Annualized return | -96.02% | 20.78% |
5Y · 2021-11-11 to 2026-08-27
| Metric | VBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -89.31% | 12.86% |
10Y · 2021-11-11 to 2026-08-27
| Metric | VBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -67.31% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |